GHRH analoog

Sermorelin kalkulaator

Arvuta iga peptiidi jaoks täpsed lahuse mahud, insuliiniühikud ja annuste arv viaali kohta.

Viaal, vesi ja annus on teada

SermorelinSee kalkulaator on seatud peptiidile Sermorelin

Peptiidi kogus (mg)

BAC-vesi (ml)

Annus (mcg)

tavaline 50-300 mcg

mcgmg

Süstla suurus

Kalibreerimine

U-100U-40

Ühikud on maht, mitte toimeaine

Ühikud mõõdavad mahtu, mitte toimeainet. 4 IU = 0,04 ml. Mitu mg selles on, sõltub segust. Kalkulaator on selle sinu eest välja arvutanud.

Peaaegu kõik insuliinisüstlad on U-100. Vali U-40 ainult siis, kui süstal on tähistatud U-40.

Sinu tulemus · reaalajas

IUmlÜhikud

Tõmba süstlasse

4IU

4 IU / 100 IU (0.040 ml)

Kontsentratsioon

2.50

mg/ml

Maht annuse kohta

0.040

Annuseid viaali kohta

annust

annuse kohta

—

Sermorelin

Põhiandmed

Sagedus: 1–3x daily
Tavaline vahemik: 50-300 mcg

Sünonüümid

GHRH(1-29)-amideGRF(1-29)-NH2

Teadusprofiil

Sermorelin peptiidileksikonis: mehhanism, tõendus ja allikad

→

What Is Sermorelin?

Sermorelin is a synthetic analog of human growth hormone-releasing hormone (GHRH). It corresponds to the first 29 amino acids of natural GHRH(1-44) and is therefore also referred to as GHRH(1-29) or GRF(1-29). This truncated fragment is notable because the first 29 amino acids already contain the complete biologically active core of the molecule. As a result, Sermorelin exerts essentially the same agonist activity at the GHRH receptor as the full-length natural hormone, while being a shorter and simpler sequence to manufacture. In the pharmaceutical literature, Sermorelin is known by the research designation GRF 1-29 and by the historical trade names Geref and sermorelin acetate.

Sermorelin is considered the classic, in a sense original GHRH peptide and was used in research long before the newer, more heavily stabilized variants. It has been studied in the diagnostic assessment of pituitary function and in research into the age-related decline of growth hormone production. Compared to the more modern GHRH analogs CJC-1295 (no DAC) and Tesamorelin, Sermorelin is chemically unmodified. It carries no protective group against enzymatic degradation, which is why its biological half-life is very short.

An important point for understanding: Sermorelin is not a growth hormone, nor is it a ghrelin-type secretagogue. It does not supply GH from an external source — it prompts the pituitary gland to release more of the body's own growth hormone. Because the stimulus only amplifies the natural releasing signal, the regulating mechanisms of the hypothalamic-pituitary axis, in particular the inhibitory action of somatostatin, remain intact. This mechanism fundamentally distinguishes Sermorelin from direct substitution with recombinant growth hormone and shapes its tolerability profile.

Mechanisms of Action

Sermorelin acts exclusively through the GHRH receptor axis and the downstream GH-IGF-1 cascade. Its key mechanisms can be summarized as follows:

GHRH receptor agonism: Sermorelin binds selectively to the GHRH receptor on the somatotroph cells of the pituitary gland. This binding activates the cAMP signaling pathway inside the cell and triggers the synthesis and release of growth hormone. Because the active GHRH(1-29) fragment contains the full receptor-binding core, its affinity is comparable to that of the natural hormone.
Preservation of pulsatile GH release: Sermorelin amplifies the natural releasing signal rather than overwriting the endogenous rhythm. The characteristic pulsatile release of growth hormone, in particular the pronounced nocturnal pulses, is preserved. What is enhanced is primarily the amplitude of those pulses, not their timing.
Rise in IGF-1: The additional growth hormone released stimulates the liver to produce insulin-like growth factor 1 (IGF-1). IGF-1 mediates much of the anabolic and tissue-directed activity of the GH axis and serves in research as a central biomarker for assessing the efficacy of a protocol.
Preservation of the feedback loop: Because the hypothalamus can continue to release somatostatin, which restrains GH release, the negative feedback of the axis remains intact. This physiological brake limits the risk of excessive GH levels and distinguishes Sermorelin from a constant exogenous GH supply.
Dependence on a functioning pituitary: Sermorelin can only release GH if the pituitary has the corresponding reserves. Where pituitary function is severely impaired, the response is correspondingly small. For exactly this reason, Sermorelin was historically used as a diagnostic stimulation test to assess GH reserve.
Very short duration of action: Sermorelin is not chemically protected against degradation by dipeptidyl peptidase-4 (DPP-4). It is therefore rapidly cleaved by enzymes, which explains its short half-life of only about 10 to 20 minutes. The signal is sharply defined and tightly time-limited, but it also fades just as quickly.

Dosage Calculation

Sermorelin is typically administered subcutaneously in research, often in the evening before sleep, to support the natural nocturnal GH pulse. A slow titration ramp is not strictly required, but starting at the lower end of the dose range is a reasonable precaution for observing individual tolerability.

Standard Dosing Parameters

Conservative dose: 50 mcg (0.05 mg) per injection
Standard dose: 100 mcg (0.10 mg) per injection
Higher range: 200-300 mcg (0.20-0.30 mg) per injection
Frequency: once to three times daily, with evening administration preferred
Typical syringe: 0.3 mL insulin syringe (29-31 gauge, 6-8 mm needle)
Common vial sizes: 2 mg and 5 mg lyophilized powder

Example Calculation: 2 mg Vial with 2 mL BAC Water

The most common vial size for Sermorelin is 2 mg. Adding 2 mL of bacteriostatic water gives a concentration of 1 mg/mL (1,000 mcg/mL). This concentration makes small volumes much easier to read on an insulin syringe.

50 mcg dose: 50 ÷ 1000 = 0.05 mL (5 units on a U100 syringe)
100 mcg dose: 100 ÷ 1000 = 0.10 mL (10 units)
200 mcg dose: 200 ÷ 1000 = 0.20 mL (20 units)
300 mcg dose: 300 ÷ 1000 = 0.30 mL (30 units)

At 100 mcg once daily, a 2 mg vial provides 20 days of dosing. A 5 mg vial with 2 mL of BAC water yields 2.5 mg/mL, so a 100 mcg dose then corresponds to just 0.04 mL (4 units). Use the Sermorelin calculator above to compute exact volumes for any vial size, reconstitution volume, and target dose.

Injection Site Selection

Sermorelin is administered subcutaneously into the fatty tissue beneath the skin, most commonly into the abdomen in the area around the navel. The outer thigh is also a suitable site. Injection sites should be rotated from day to day to avoid local irritation and hardening of the tissue. The very short half-life of about 10 to 20 minutes means the peptide acts quickly and is cleared just as fast. Consistent, time-aligned administration is therefore more important for a stable research protocol than with longer-acting GHRH analogs.

Reconstitution

Sermorelin is supplied as a lyophilized (freeze-dried) powder in sealed vials and must be reconstituted with bacteriostatic water (BAC water) before use. BAC water contains 0.9% benzyl alcohol, which inhibits microbial growth and extends the usable window of the reconstituted solution. Sterile water for injection is not suitable for multi-dose vials because it offers no preservation.

Step-by-Step Reconstitution Protocol

Gather supplies: Sermorelin vial, bacteriostatic water vial, alcohol swabs, a sterile draw needle (18-21 gauge), and your insulin syringe for injection.
Wipe the rubber septa of both vials with fresh alcohol swabs and allow them to air-dry for about 30 seconds. Do not touch or blow on the septa after cleaning.
Draw the desired volume of BAC water (2 mL is standard for a 2 mg vial) into the draw syringe.
Insert the needle into the peptide vial at an angle, directing the tip toward the inner glass wall rather than the powder cake. A direct jet onto the lyophilizate can shear peptide bonds and damage the delicate molecule.
Slowly push the plunger, allowing the BAC water to run down the inside wall of the vial and gently wet the powder from the side.
Gently swirl or roll the vial between your palms until the powder is completely dissolved. The solution should appear clear and colorless. Do not shake or vortex the vial, as shear forces can denature the peptide.
Label the vial with the reconstitution date and concentration (e.g., "Sermorelin 1 mg/mL, reconstituted [date]").

If the solution appears cloudy, discolored, or contains visible particulate matter, discard the vial and do not inject it.

Storage and Shelf Life

Lyophilized powder (unreconstituted): Store at −20°C for long-term storage, where the powder remains stable for many months. Short-term storage at 2-8°C in the refrigerator is acceptable. Keep away from light and moisture and do not leave at room temperature for extended periods.
Reconstituted solution: Store in the refrigerator at 2-8°C. Sermorelin is more fragile once dissolved than more robust peptides, so the solution should be used promptly, typically within about 2 to 3 weeks. Keep the vial upright and away from light, and write the reconstitution date prominently on the label.
Do not freeze reconstituted peptide. Freeze-thaw cycles cause protein aggregation and loss of activity. Once reconstituted, the vial must remain refrigerated throughout its use window.
Transport: Use an insulated cooler with an ice pack for any travel lasting more than 1-2 hours. Commercial insulated medication pouches maintain 2-8°C for 24-48 hours. Avoid exposure to temperatures above 25°C during transport.

Side Effects and Safety Profile

Sermorelin is among the longest-known GHRH peptides and has been used in humans in diagnostic and age-related research, among other settings. Because its effects are mediated through enhanced growth hormone and IGF-1 activity, the effects to watch for are closely tied to the known actions of the GH axis. All use remains in the research domain.

Commonly Reported Observations

Injection site reactions such as redness, itching, mild swelling, or brief discomfort. These are among the most frequently documented observations and can be reduced by consistently rotating injection sites.
Transient facial flushing or a sensation of warmth shortly after injection, which usually subsides within a few minutes.
Mild headache or a feeling of heaviness or lightheadedness, particularly at the start of a protocol. These observations are usually mild and temporary.
An altered taste in the mouth or mild nausea immediately after injection, more common when the dose is administered rapidly.

Less Common or Theoretical Concerns

Effect on glucose metabolism: Growth hormone can reduce insulin sensitivity and affect fasting blood glucose. Because of Sermorelin's very short duration of action, this effect is considered limited, but it should be taken into account in individuals with impaired glucose tolerance.
Fluid retention and joint discomfort: Enhanced GH activity can theoretically cause mild water retention as well as joint or muscle stiffness. With Sermorelin, such observations are less frequent than with more heavily stabilized GHRH analogs because its peaks are low and short-lived.
Persistently elevated IGF-1 levels: A sustained increase in IGF-1 is theoretically relevant, since IGF-1 promotes cell growth. Concurrent monitoring of IGF-1 values is common in longer research protocols.

Contraindications

Active cancer or history of malignancy, as increased GH-IGF-1 activity is theoretically unfavorable
Pituitary disorders, recent pituitary surgery, or radiation to the head region
Pregnancy and breastfeeding (insufficient safety data)
Known hypersensitivity to Sermorelin or any other component of the preparation

At standard research doses, Sermorelin has been described in the published literature as largely well tolerated. Nonetheless, given its action on the endocrine GH axis, caution is warranted, and consultation with a qualified physician is strongly recommended.

Combinations and Stacks

Sermorelin Within the GHRH Class

Sermorelin belongs to the family of GHRH analogs and is closely related functionally to CJC-1295 (no DAC) and Tesamorelin. All three stimulate the same GHRH receptor but differ in stability and duration of action. Sermorelin corresponds to the unmodified GHRH(1-29) fragment with a very short half-life, CJC-1295 without DAC is a modified fragment with improved stability, and Tesamorelin is a fully stabilized GHRH(1-44) analog with the most extensive body of clinical data.

Sermorelin Plus a GHRP — The Dual-Axis Approach

A widely used research concept combines a GHRH analog with a GHRP (growth hormone releasing peptide) such as Ipamorelin. The two peptide classes act through distinct, complementary receptors:

Sermorelin amplifies the releasing signal at the GHRH receptor and increases the amplitude of GH pulses.
Ipamorelin acts at the ghrelin receptor and additionally dampens the inhibitory effect of somatostatin, allowing a larger share of the available GH reserve to be released.
The combined stimulus on both axes produces a more pronounced GH response in models than either peptide achieves alone, without abolishing the pulsatile release pattern.

Other GHRPs discussed alongside Sermorelin in comparable research contexts include Hexarelin, GHRP-6, and GHRP-2. Because the GH-IGF-1 axis is stressed more heavily by a combined stimulus, conservative doses, careful monitoring of glucose and IGF-1, and planned breaks are sensible in research protocols.

Sermorelin as a Standalone

Sermorelin is also used as a standalone compound in research, particularly when the goal is to study a stimulus that is as physiological as possible and closely modeled on natural GHRH. Its very short duration of action makes Sermorelin a well-controlled single peptide whose effects can be tracked through the IGF-1 biomarker. A simple monotherapy protocol is often the first step before more complex combinations are evaluated.

Frequently Asked Questions

How does Sermorelin differ from growth hormone (HGH)?

Sermorelin is not a growth hormone but a GHRH analog. It prompts the pituitary to release more of the body's own growth hormone, whereas HGH supplies the hormone directly from an external source. The key difference lies in feedback: with Sermorelin, the inhibitory action of somatostatin is preserved, so GH levels cannot rise without limit. In addition, the natural, pulsatile release pattern is maintained, which is not the case with a constant supply of HGH.

What is the difference between Sermorelin and CJC-1295?

Both are GHRH analogs and stimulate the same receptor. Sermorelin corresponds to the unmodified GHRH(1-29) fragment and is broken down very quickly. CJC-1295 without DAC is a modified fragment with targeted amino acid substitutions that make it more resistant to enzymatic degradation, which is why its duration of action is longer. Sermorelin is therefore the closest to natural GHRH, while CJC-1295 was optimized for extended stability.

Why is Sermorelin used in the evening?

The body's largest natural GH release occurs during the first hours of deep sleep. An evening injection of Sermorelin is intended to amplify this physiological pulse rather than create an additional, off-schedule GH surge. The very short half-life of about 10 to 20 minutes suits this concept well, as the signal stays tightly time-limited and coincides with the nocturnal pulse.

Why does Sermorelin have such a short half-life?

Sermorelin is chemically unmodified and structurally closely matches the natural GHRH fragment. It carries no protective group against dipeptidyl peptidase-4 (DPP-4), an enzyme that rapidly cleaves GHRH-type peptides. As a result, Sermorelin is broken down very quickly, with a half-life of only about 10 to 20 minutes. This short duration of action is intentional, as it produces a sharply defined, physiologically natural signal.

Should Sermorelin be used in a fasted state?

Because growth hormone and insulin partly act against each other, a high insulin level following a carbohydrate-rich meal dampens the GH response. Research protocols therefore often recommend timing the injection with a gap after the last substantial meal. With evening administration before sleep, this gap often arises naturally.

Is post-cycle therapy (PCT) required?

Sermorelin does not act on the hypothalamic-pituitary-gonadal axis and does not suppress the body's own testosterone production. A classic PCT, of the kind common after androgenic substances, is therefore not required. Because Sermorelin only amplifies the natural GHRH signal, the pituitary generally recovers after discontinuation without any further measures.

Is Sermorelin prohibited in sports drug testing?

Yes. Sermorelin falls under the WADA prohibited list as a growth hormone-releasing factor and GH secretagogue and is banned in sport both in and out of competition. Athletes subject to WADA-compliant testing should treat Sermorelin as a prohibited substance and verify the anti-doping rules applicable to their sport before any use.

Can Sermorelin be mixed with a GHRP in the same syringe?

Some research protocols combine a GHRH analog and a GHRP in a single syringe immediately before injection. In general, however, it is safer to reconstitute each peptide individually and inject them separately, since their combined stability in solution is not well characterized. Separate injections at adjacent sites add minimal inconvenience while eliminating the risk of dosing errors.

Medical Disclaimer: The information on this page is provided for educational and research purposes only. Sermorelin is not an approved drug or medical treatment within the scope of this offering and is provided strictly for research use. Nothing on this page constitutes medical advice, diagnosis, or a recommendation to use any specific compound. Always consult a qualified healthcare professional before beginning any peptide protocol. BergdorfBio assumes no liability for the use or misuse of the information presented here.

Samm-sammult

Kuidas peptiidi lahustada

Pulbrist valmis süstlani viie sammuga. Ülalolev kalkulaator annab kogused automaatselt.

011
Valmista BAC-vesi ette
Lase viaalil ja veel jõuda toatemperatuurini. Pühi mõlemad kummikorgid alkoholilapiga.
022
Tõmba vesi süstlasse
Tõmba kalkulaatori soovitatud BAC-vee kogus suurema süstlaga.
033
Lisa aeglaselt
Lase veel voolata mööda peptiidiviaali siseseina, ära pihusta seda otse pulbrile.
044
Lase lahustuda
Keeruta viaali õrnalt, ära raputa. Pulber lahustub selgeks 1-2 minuti jooksul.
055
Tõmba annus süstlasse
Tõmba insuliinisüstlaga täpselt arvutatud kriipsuni. Valmis.

Viide

Annused ja viaalisuurused peptiidi kaupa

Tavalised algväärtused orienteerumiseks. Iga rida avab selle peptiidi kalkulaatori.

Peptiid	Kategooria	Tavaline annus	Viaalisuurused	BAC (algus)	Saadaval	Arvuta
VIP	Neuropeptiidide uurimine	-	10 mg	2 ml	Ainult kalkulaator	Arvuta
Retatrutide	GLP-1/GIP/GCG	0,5-12 mg	2 / 5 / 10 / 15 mg	2 ml	Ainult kalkulaator	Arvuta
Cagrilintide	Amüliini analoog	-	5 mg	2 ml	Ainult kalkulaator	Arvuta
Semaglutide	GLP-1	0,25-2,4 mg	2 / 5 / 10 mg	2 ml	Ainult kalkulaator	Arvuta
Tirzepatide	GLP-1/GIP	2,5-15 mg	10 / 15 / 20 / 30 / 60 / 90 mg	2 ml	Ainult kalkulaator	Arvuta
GHK-Cu	Vaskepeptiid	1-4 mg	10 / 20 / 50 mg	5 ml	Ainult kalkulaator	Arvuta
AHK-Cu	Vaskepeptiid	-	100 mg	5 ml	Ainult kalkulaator	Arvuta
BPC-157	Kudede taastamine	0,2-0,5 mg	2 / 5 / 10 mg	2 ml	Ainult kalkulaator	Arvuta
TB-500	Thymosin Beta-4	2-5 mg	2 / 5 / 10 mg	2 ml	Ainult kalkulaator	Arvuta
CJC-1295 (ilma DAC-ta)	GHRH analoog	100-200 mcg	2 / 5 / 10 mg	2 ml	Ainult kalkulaator	Arvuta
Ipamorelin	GHRP	200-300 mcg	2 / 5 mg	2 ml	Ainult kalkulaator	Arvuta
AOD-9604	Rasvade ainevahetus	250-500 mcg	2 / 5 mg	2 ml	Ainult kalkulaator	Arvuta
PT-141	Bremelanotide	-	2 / 5 / 10 mg	2 ml	Ainult kalkulaator	Arvuta
MOTS-c	Mitokondriaalne	5-10 mg	5 / 10 mg	2 ml	Ainult kalkulaator	Arvuta
Selank	Anksiolüütiline	150-500 mcg	2 / 5 / 10 mg	2 ml	Ainult kalkulaator	Arvuta
SS-31	Elamipretide	0,1-1 mg	5 / 10 mg	2 ml	Ainult kalkulaator	Arvuta
Glow Stack	Stack	0,5-2 mg	70 mg	3 ml	Ainult kalkulaator	Arvuta
Klow Stack	Stack	0,5-2 mg	55 mg	3 ml	Ainult kalkulaator	Arvuta
Melanotan II	Melanokortiin	100-1000 mcg	5 / 10 mg	2 ml	Ainult kalkulaator	Arvuta
Melanotan I	Melanokortiin	-	5 / 10 mg	2 ml	Ainult kalkulaator	Arvuta
Sermorelin	GHRH analoog	50-300 mcg	5 mg	2 ml	Ainult kalkulaator	Arvuta
Tesamorelin	GHRH analoog	1-2 mg	10 / 20 mg	2 ml	Ainult kalkulaator	Arvuta
Thymosin Alpha-1	Tüümusepetiid	0,8-3,2 mg	1.6 / 5 / 10 mg	1 ml	Ainult kalkulaator	Arvuta
Epithalon	Pikaajalisus	2-10 mg	10 / 20 / 50 mg	2 ml	Ainult kalkulaator	Arvuta
KPV	Immuunsüsteem / barjäär	100-1000 mcg	5 / 10 mg	2 ml	Ainult kalkulaator	Arvuta
HGH Fragment 176-191	Metaboolne fragment	100-500 mcg	2 / 5 / 10 mg	2 ml	Ainult kalkulaator	Arvuta
Semax	Kognitiivne	100-1000 mcg	10 / 30 mg	2 ml	Ainult kalkulaator	Arvuta
N-Acetyl Semax	Kognitiivne	100-1000 mcg	5 / 10 mg	2 ml	Ainult kalkulaator	Arvuta
Hexarelin	GHRP	50-200 mcg	2 / 5 mg	2 ml	Ainult kalkulaator	Arvuta
GHRP-6	GHRP	50-300 mcg	2 / 5 mg	2 ml	Ainult kalkulaator	Arvuta
GHRP-2	GHRP	50-250 mcg	2 / 5 mg	2 ml	Ainult kalkulaator	Arvuta
DSIP	Uni	50-500 mcg	10 mg	2 ml	Ainult kalkulaator	Arvuta
5-Amino-1MQ	Metaboolne	2,5-10 mg	10 mg	2 ml	Ainult kalkulaator	Arvuta
Pinealon	Uurimispeptiid	-	10 mg	2 ml	Ainult kalkulaator	Arvuta
Survodutide	GLP-1/glükagoon	-	10 mg	2 ml	Ainult kalkulaator	Arvuta
Kisspeptin-10	KISS1R / GPR54	-	10 mg	2 ml	Ainult kalkulaator	Arvuta
HGH 191AA	Kasvuhormoon	1-5 mg	10 mg	1 ml	Ainult kalkulaator	Arvuta
NAD+	Pikaajalisus / kofaktor	100-500 mg	1000 mg	10 ml	Ainult kalkulaator	Arvuta

Väärtused on mõeldud orienteerumiseks uurimiskontekstis ega asenda professionaalset nõuannet.

Miks täpne annustamine oluline on

Kontsentratsiooni ja süstemahu õige arvutamine tundub tühine, kuid on kõige sagedasem veaallikas. Isegi 10 % suurune arvutusviga lahuse valmistamisel tähendab, et saad kas liiga vähe toimeainet või manustad kogemata üleannuse.

Lüofiliseeritud peptiide müüakse milligrammides ja need lahustatakse bakteriostaatilises vees (BAC-vesi). Peptiidi ja vee suhe määrab kontsentratsiooni ja sellest tuleneb, mitu ühikut insuliinisüstlale tõmbad. Insuliinisüstlaid gradueeritakse ühikutes, mitte milligrammides. Kalkulaator teeb selle ümberarvutuse ära, sealhulgas mõistlikkuse kontrolli kõige ohtlikuma vea vastu: mg ja mcg segiajamine.

KKK

Korduma kippuvad küsimused

Mis vahe on mcg ja mg vahel?

Milligramm (mg) on ühik, milles lüofiliseeritud peptiide müüakse, näiteks „5 mg BPC-157". Mikrogramm (mcg) mõõdab üksikannust, näiteks „250 mcg süsti kohta". 1 mg = 1000 mcg. Kalkulaator teeb ümberarvutuse automaatselt ja hoiatab, kui sisestus tundub segiaetud olevat.

Mida tähendab „U-100" minu insuliinisüstlal?

U-100 tähendab, et süstal on kalibreeritud 100 ühikule milliliitri kohta. 100 IU = 1 ml, seega 10 IU = 0,10 ml, sõltumata sellest, mis süstlas on. IU arvutus põhineb täpselt sellel seosel.

Miks näitab kalkulaator mõnikord väga väikeseid mahtusid?

Palju peptiidi ja vähe vett teeb lahuse väga kontsentreerituks, mistõttu maht annuse kohta on tilluke ja raskesti loetav. Kasuta segamise abivahendit: see leiab veekoguse, millega tekib puhas ja hästi loetav kriips.

Kui kaua lahustatud peptiid püsib?

Külmkapis 2-8 °C juures tavaliselt 21-30 päeva. Märgista viaalile lahuse valmistamise kuupäev. Hägused lahused või osakesed ei kõlba.

Kuidas kalkulaator töötab segude, näiteks Glow Stacki puhul?

Segud sisaldavad ühes viaalis mitut toimeainet. Vali peptiidiks lihtsalt segu: kalkulaator näitab lisaks, kui palju igat komponenti sinu süstis on. Mitme eraldi viaali kombinatsiooni jaoks kasuta Stack Builderit.

Kas kalkulaator tuleb iga kord uuesti täita?

Ei. Sinu viimased seaded salvestatakse lokaalselt brauserisse ja taastatakse järgmisel külastusel. Arvutusi saad ka ajaloost tagasi kutsuda, protokollina salvestada või lingina jagada.

Seotud peptiidid

CJC-1295 (ilma DAC-ta)GHRH analoog IpamorelinGHRP HexarelinGHRP GHRP-6GHRP GHRP-2GHRP

Kõik kalkulaatorid

Vali peptiid

Vali peptiid, et avada selle kalkulaatorileht eeltäidetud väärtustega.

Sermorelin kalkulaator

Põhiandmed

What Is Sermorelin?

Mechanisms of Action

Dosage Calculation

Standard Dosing Parameters

Example Calculation: 2 mg Vial with 2 mL BAC Water

Injection Site Selection

Reconstitution

Step-by-Step Reconstitution Protocol

Storage and Shelf Life

Side Effects and Safety Profile

Commonly Reported Observations

Less Common or Theoretical Concerns

Contraindications

Combinations and Stacks

Sermorelin Within the GHRH Class

Sermorelin Plus a GHRP — The Dual-Axis Approach

Sermorelin as a Standalone

Frequently Asked Questions

How does Sermorelin differ from growth hormone (HGH)?

What is the difference between Sermorelin and CJC-1295?

Why is Sermorelin used in the evening?

Why does Sermorelin have such a short half-life?

Should Sermorelin be used in a fasted state?

Is post-cycle therapy (PCT) required?

Is Sermorelin prohibited in sports drug testing?

Can Sermorelin be mixed with a GHRP in the same syringe?

Kuidas peptiidi lahustada

Valmista BAC-vesi ette

Tõmba vesi süstlasse

Lisa aeglaselt

Lase lahustuda

Tõmba annus süstlasse

Annused ja viaalisuurused peptiidi kaupa

Miks täpne annustamine oluline on

Korduma kippuvad küsimused

Seotud peptiidid

Vali peptiid

VIP

Retatrutide

Cagrilintide

Semaglutide

Tirzepatide

GHK-Cu

AHK-Cu

BPC-157

TB-500

CJC-1295 (ilma DAC-ta)

Ipamorelin

AOD-9604

PT-141

MOTS-c

Selank

SS-31

Glow Stack

Klow Stack

Melanotan II

Melanotan I

Tesamorelin

Thymosin Alpha-1

Epithalon

KPV

HGH Fragment 176-191

Semax

N-Acetyl Semax

Hexarelin

GHRP-6

GHRP-2

DSIP

5-Amino-1MQ

Pinealon

Survodutide

Kisspeptin-10

HGH 191AA

NAD+

Sermorelin kalkulaator

Põhiandmed

What Is Sermorelin?

Mechanisms of Action